Newsnote from the U.S. Food and Drug Administration

Depakote (Divalproex) Approved For Migraine Prevention

NEW YORK, NY -- November 13, 2001 -- The FDA Guide recently approved Depakote ER (divalproex [Image] sodium extended-release tablets), a once-a-day formulation for the prevention of migraine headaches in adults.

Developed by Abbot Laboratories, Depakote ER is currently available by prescription in the U.S. An estimated 28 million Americans suffer from migraines.

Migraines can be debilitating, and can disrupt daily activities and jobperformance. Statistics show migraine sufferers miss 157 million workdays every year at a cost of as much as 17 million dollars to the U.S. economy.

By taking Depakote ER just once a day, frequent migraine sufferers can prevent migraines before they start, and enjoy their lives again.

Related links: Depakote and Abbott Laboratories.

Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.